The CBARP Knockout HeLa Polyclonal Cells product constitutes a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely utilized human cervical epithelial carcinoma HeLa cell line. This model enables targeted disruption of the CBARP gene, which encodes a regulatory protein that modulates voltage-gated calcium channel (VGCC) activity. The polyclonal format provides a heterogeneous pool of cells with varied CBARP gene disruptions, facilitating robust loss-of-function studies without clonal selection biases. Researchers can employ this knockout model to dissect CBARP-dependent modulation of calcium signaling and its downstream cellular consequences, using standard techniques such as western blotting and RT-qPCR to confirm CBARP ablation.
The host HeLa cell line, isolated from a cervical adenocarcinoma of a 31-year-old African American woman in 1951, is an immortalized, HPV18-positive, aneuploid epithelial model extensively employed in cancer research. HeLa cells represent a canonical system for studying oncogenic processes, including proliferation, migration, and signal transduction. Their rapid growth, ease of transfection, and well-characterized proteome render them ideally suited for genetic manipulation and subsequent phenotypic analyses. In the context of cervical cancer biology, HeLa cells retain key signaling networks that intersect with VGCC-mediated calcium dynamics, providing a relevant platform for investigating CBARP function in tumorigenesis.
CBARP encodes a protein that interacts specifically with the CACNB2 subunit, a key auxiliary component of voltage-gated calcium channels such as CaV1.2 (CACNA1C) and CaV1.3 (CACNA1D). This interaction modulates channel trafficking, membrane expression, and gating properties, thereby fine-tuning calcium influx. Downstream, CBARP influences calcium-dependent signaling cascades, including the calcineurin/NFAT pathway and Ca2+/calmodulin-dependent protein kinase II (CaMKII) axes. These pathways are activated by calcium/calmodulin-dependent kinases and protein kinase C, which respond to upstream stimuli such as G-protein coupled receptor agonists. Loss of CBARP disrupts this regulatory node, altering calcium-dependent transcription mediated by NFAT and CREB, and impacting calcium-regulated enzymes like calmodulin and CaMKII, ultimately affecting processes such as cell cycle progression and MAPK/ERK signaling.
In the HeLa adenocarcinoma model, CBARP disruption holds particular significance due to the interplay between calcium homeostasis and oncogenic signaling. Aberrant VGCC function and calcium fluxes have been implicated in cervical cancer cell proliferation and motility. The CBARP knockout cells permit direct interrogation of how the CACNB2?CCBARP interaction modulates calcium-dependent pathways that drive tumor cell behavior. By comparing CBARP-disrupted HeLa cells to parental controls, researchers can delineate the contribution of this regulatory protein to calcium-mediated activation of NFAT-driven gene expression and CaMKII-mediated cytoskeletal rearrangements. This model is thus instrumental for evaluating the role of CBARP in processes central to cancer progression, such as epithelial?Cmesenchymal transition and resistance to apoptotic stimuli, within a relevant cellular context.
This polyclonal knockout cell population is ideally suited for a wide range of research applications. Users can perform calcium imaging using Fluo-4 or Fura-2 to quantify intracellular calcium transients, electrophysiological patch-clamp recordings to assess VGCC currents, and cell proliferation (MTT/CCK-8) or migration (Boyden chamber) assays to link CBARP loss to phenotypic outcomes. Co-immunoprecipitation studies can further validate disrupted CBARP?CCACNB2 interactions. These cells also serve as a screening tool for calcium channel modulators or compounds targeting the MAPK/ERK pathway. For additional technical details or to discuss custom applications, please contact Ascent Research.
